TheTechno Optimist.

KB407Krystal Biotech—Krystal reports KB407 Phase 1 positive: CFTR expression confirmed in CF lungsKB407Krystal Biotech—FDA grants platform-technology designation to HSV-1 vector in KB407VyjuvekKrystal Biotech—Vyjuvek Q2 2026 revenue $119.2M; cumulative $965.9M since launch

KB407

by Krystal BiotechUS

Restore CFTR function in CF lungs via inhaled gene therapy to improve mucociliary clearance and reduce infection.

ProtoStage 2 of 5

Phase 1 CORAL-1 ongoing. January 2026 update confirmed CFTR delivery and expression.

Updated Apr 2026Checked 11 Oct0 updates this week

Milestones

Next · Registrational design alignment with FDA
  1. CORAL-1 Phase 1 initiated2025Complete.
  2. Positive update: CFTR expression confirmedJan 2026Complete.
  3. HSV-1 vector platform designation from FDAApr 2026Complete.
  4. Registrational design alignment with FDATarget Q4 2026Not yet reached.
  5. Registrational study initiationTarget 2027Not yet reached.

Most important updates

Upcoming

  1. Q4 2026Registrational design alignment with FDA (next)
  2. 2027Registrational study initiation
Primer